Search: Search
User  Name:   
Join Free
What is Remember My ID  
Newspaper In Education
State News
Vendor News
Calendar of Events
Trade Shows
Career Section
Resource Directory
Contact Us
Jump to Story
Please enter the story number in the box obove you would like to immediately access
Online Subscription Form
Media Kit
Web Hosting Hospital Newspaper
New Jersey
Hackensack University Medical Center Participates in a Study to Help People with Seizures
Story Number is : 031217135
Hackensack University Medical

Hackensack University Medical Center, part of the Hackensack Meridian Health family, is participating in an emergency medicine research study designed to try to save and improve the lives of people who experience a seizure.

The Established Status Epilepticus Treatment Trial (ESETT) is specific to people with seizures lasting longer than five minutes, which fail to respond to a full dose of a benzodiazepine (like valium).

“The goal of this study is to learn which treatment stops seizures most effectively and quickly,” said Joseph Feldman, M.D., chair, Emergency Services at HackensackUMC and ESETT principal investigator.

ESETT, will look at three commonly used medicines given in the emergency department to treat Established Status Epilepticus (ESE): phenytoin (fPHT), valproic acid (VPA) and levetiracetam (LVT).

“We are looking for the medication that might out-perform the rest,” said Chinwe Ogedegbe, M.D., section chief, Research, Emergency and Trauma Center at HackensackUMC. “That might be our first-line medication at the end of the day.”
Dr. Feldman and Dr. Ogedegbe are working in conjunction with Usha Avva, M.D. in the Pediatric Emergency Department and Georges Ghacibeh, M.D., in the Department of Neurology to gain full participation in the study.

Status Epilepticus (SE) is a life-threatening condition in which the brain is in a state of persistent seizure. A person whose seizure does not stop even after receiving a full dose of medicine is considered to have ESE.

“Just like with a stroke, time is brain with status epilepticus” says Florian Thomas, M.D., Ph.D., chair, Neuroscience Institute and chief, Neurology Service, at HackensackUMC. Long-lasting seizures can affect a person’s ability to think, remember, work or function independently. Seizures can cause permanent brain damage or even death.
There are approximately 120,000 to 180,000 episodes of SE each year in the U.S. About one third of SE patients continue to have a seizure that will not stop or ESE.
For any research study at HackensackUMC, the Institutional Review Board will make sure that it adheres to the highest ethical standards. Researchers typically gain consent prior to a study. Given the emergent nature of this condition, a person having a seizure is not able to give consent at that time. Since a seizure that will not stop on its own must be treated quickly, the person will be automatically enrolled in the study during treatment. Once the patient’s representative is located or the patient wakes up, permission to continue will be requested.

There are two methods for declining participation in the study prior to treatment. People with an existing medic alert tag or bracelet can add “ESETT study declined” to the tag. An opt-out bracelet with the words “ESETT declined” can also be sent upon request.
HackensackUMC is participating in this trial through the Philadelphia Neurological Emergencies Treatment Trials, a National Institute of Neurological Disorders and Stroke sponsored network of hub and spoke hospitals conducting emergency neurological research.

For more information including an option to decline participation and to share your opinions about this study, visit

More News From This State
Hospital Newspaper
Career Section click here
Hospital Newspaper
Advertise Here
Career Section click here
Advertise Here
Career Section click here
Advertise Here
Hospital Newspaper Columns
Advertise Here
Advertise Here